Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1259-1266

  Oh, Seung Hyun ^a,e   Kim, Woo Young ^b,e   Lee, Ok Hee ^d,g   Kang, Ju Hee ^c,d   Woo, Jong Kyu ^f   Kim, Jai Hyun ^e   Glisson, Bonnie ^e   Lee, Ho Young ^f  

^a Gachon University   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c National Cancer Center   (South Korea)

^d Chung Ang University   (South Korea)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Seoul National University   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; RINFABATE; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL INVASION; CELL MIGRATION; CHORIOALLANTOIS; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TONGUE TUMOR; TUMOR MODEL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOVIRIDAE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEAD AND NECK NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; MICE, KNOCKOUT; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863337165     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02301.x     Document Type: Article

References (39)

1. van Moorselaar RJ, Voest EE Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002; 197: 239-50.
2. Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. Kim WY, Lee HY Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 2009; 276: 4653-64.
4. Ryan HE, Lo J, Johnson RS HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-15.
5. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-8.
6. Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T, Hashizume K IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J 1999; 46(Suppl): S59-62.
7. Menu E, Jernberg-Wiklund H, De Raeve H et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 2007; 121: 1857-61.
8. Moser C, Schachtschneider P, Lang SA et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008; 44: 1577-86.
9. Granata R, Trovato L, Lupia E et al. Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost 2007; 5: 835-45.
10. Huang SS, Ling TY, Tseng WF et al. Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. FASEB J 2003; 17: 2068-81.
11. Bhattacharyya N, Pechhold K, Shahjee H et al. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 2006; 281: 24588-601.
12. Ikonen M, Liu B, Hashimoto Y et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA 2003; 100: 13042-7.
13. Lee HY, Chun KH, Liu B et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002; 62: 3530-7.
14. Chang KH, Chan-Ling T, McFarland EL et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 2007; 104: 10595-600.
15. Lofqvist C, Chen J, Connor KM et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007; 104: 10589-94.
16. Kielczewski JL, Jarajapu YP, McFarland EL et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 2009; 105: 897-905.
17. Oh SH, Kim WY, Kim JH et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 653-61.
18. Liu B, Lee KW, Anzo M et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007; 26: 1811-9.
19. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology 2005; 146: 1523-31.
20. Lee HY, Moon H, Chun KH et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 2004; 96: 1536-48.
21. Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ, Kim KW Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Int J Cancer 2000; 87: 269-75.
22. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
23. Oh SH, Woo JK, Yazici YD et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007; 99: 949-61.
24. Oh SH, Woo JK, Jin Q et al. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 2008; 122: 5-14.
25. Philpott NJ, Nociari M, Elkon KB, Falck-Pedersen E Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci USA 2004; 101: 6200-5.
26. Platz EA, Pollak MN, Rimm EB et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999; 8: 1107-10.
27. Punglia RS, Lu M, Hsu J et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997; 46: 1619-26.
28. Tapanainen PJ, Bang P, Muller HL, Wilson K, Rosenfeld RG Hypoxia-induced changes in insulin-like growth factors and their binding proteins in pregnant rats. Horm Res 1997; 48: 227-34.
29. Franklin SL, Ferry RJ Jr, Cohen P Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003; 88: 900-7.
30. Delafontaine P, Song YH, Li Y Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 435-44.
31. Frost P, Shi Y, Hoang B, Lichtenstein A AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007; 26: 2255-62.
32. Li W, Tan D, Zhang Z, Liang JJ, Brown RE Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 2008; 20: 713-9.
33. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 2009; 29: 1172-8.
34. Firth SM, Baxter RC Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-54.
35. Nakamura E, Abreu-e-Lima P, Awakura Y et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 2006; 168: 574-84.
36. Niu X, Zhang T, Liao L et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 2012; 31: 776-86.
37. Slomiany MG, Rosenzweig SA Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol 2004; 287: C746-53.
38. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
39. Bergers G, Hanahan D Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.